Literature DB >> 32435377

Glycomimetic Based Approach toward Selective Carbonic Anhydrase Inhibitors.

Debora Pratesi1, Camilla Matassini1, Andrea Goti1,2, Andrea Angeli3, Fabrizio Carta3, Claudiu T Supuran3, Rolando Spanevello4, Francesca Cardona1,2.   

Abstract

The synthesis of selective inhibitors of human carbonic anhydrases (hCAs) is of paramount importance to avoid side effects derived from undesired interactions with isoforms not involved in the targeted pathology, and this was partially addressed with the introduction of a sugar moiety (the so-called "sugar approach"). Since glycomimetics are considered more selective than the parent sugars in inhibiting carbohydrate-processing enzyme, we explored the possibility of further tuning the selectivity of hCAs inhibitors by combining the sulfonamide moiety with a sugar analogue residue. In particular, we report the synthesis of two novel hCAs inhibitors 2 and 3 which feature the presence of a piperidine iminosugar and an additional carbohydrate moiety derived from levoglucosenone (1), a key intermediate derived from cellulose pyrolysis. Biological assays revealed that iminosugar 2 is a very strong inhibitor of the central nervous system (CNS) abundantly expressed hCA VII (K I of 7.4 nM) and showed a remarkable selectivity profile toward this isoform. Interestingly, the presence of levoglucosenone in glycomimetic 3 imparted a strong inhibitory activity toward the tumor associated hCA IX (K I of 35.9 nM).
Copyright © 2020 American Chemical Society.

Entities:  

Year:  2020        PMID: 32435377      PMCID: PMC7236246          DOI: 10.1021/acsmedchemlett.9b00590

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  19 in total

1.  Click Chemistry: Diverse Chemical Function from a Few Good Reactions.

Authors:  Hartmuth C. Kolb; M. G. Finn; K. Barry Sharpless
Journal:  Angew Chem Int Ed Engl       Date:  2001-06-01       Impact factor: 15.336

Review 2.  Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms?

Authors:  Vincenzo Alterio; Anna Di Fiore; Katia D'Ambrosio; Claudiu T Supuran; Giuseppina De Simone
Journal:  Chem Rev       Date:  2012-05-18       Impact factor: 60.622

3.  An improved synthesis of a key intermediate for (+)-biotin from D-mannose.

Authors:  Fen-Er Chen; Jian-Feng Zhao; Fang-Jun Xiong; Bin Xie; Ping Zhang
Journal:  Carbohydr Res       Date:  2007-07-18       Impact factor: 2.104

Review 4.  Carbonic anhydrases: novel therapeutic applications for inhibitors and activators.

Authors:  Claudiu T Supuran
Journal:  Nat Rev Drug Discov       Date:  2008-02       Impact factor: 84.694

5.  A class of sulfonamide carbonic anhydrase inhibitors with neuropathic pain modulating effects.

Authors:  Fabrizio Carta; Lorenzo Di Cesare Mannelli; Melissa Pinard; Carla Ghelardini; Andrea Scozzafava; Robert McKenna; Claudiu T Supuran
Journal:  Bioorg Med Chem       Date:  2015-02-21       Impact factor: 3.641

6.  Carbonic anhydrase inhibitors: synthesis of membrane-impermeant low molecular weight sulfonamides possessing in vivo selectivity for the membrane-bound versus cytosolic isozymes.

Authors:  A Scozzafava; F Briganti; M A Ilies; C T Supuran
Journal:  J Med Chem       Date:  2000-01-27       Impact factor: 7.446

7.  Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro.

Authors:  S Parkkila; H Rajaniemi; A K Parkkila; J Kivela; A Waheed; S Pastorekova; J Pastorek; W S Sly
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-29       Impact factor: 11.205

Review 8.  Carbonic anhydrase inhibitors and activators for novel therapeutic applications.

Authors:  Claudiu T Supuran
Journal:  Future Med Chem       Date:  2011-07       Impact factor: 3.808

9.  Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors.

Authors:  Yuanmei Lou; Paul C McDonald; Arusha Oloumi; Stephen Chia; Christina Ostlund; Ardalan Ahmadi; Alastair Kyle; Ulrich Auf dem Keller; Samuel Leung; David Huntsman; Blaise Clarke; Brent W Sutherland; Dawn Waterhouse; Marcel Bally; Calvin Roskelley; Christopher M Overall; Andrew Minchinton; Fabio Pacchiano; Fabrizio Carta; Andrea Scozzafava; Nadia Touisni; Jean-Yves Winum; Claudiu T Supuran; Shoukat Dedhar
Journal:  Cancer Res       Date:  2011-03-17       Impact factor: 12.701

10.  Cycloaddition and one-carbon homologation studies in the synthesis of advanced iridoid precursors.

Authors:  Anne T Stevens; Mino R Caira; James R Bull; Kelly Chibale
Journal:  Org Biomol Chem       Date:  2009-07-08       Impact factor: 3.876

View more
  4 in total

Review 1.  Levoglucosenone: Bio-Based Platform for Drug Discovery.

Authors:  Jason E Camp; Ben W Greatrex
Journal:  Front Chem       Date:  2022-05-31       Impact factor: 5.545

2.  A benzoxazole derivative as an inhibitor of anaerobic choline metabolism by human gut microbiota.

Authors:  Moustafa T Gabr; David Machalz; Szymon Pach; Gerhard Wolber
Journal:  RSC Med Chem       Date:  2020-08-28

3.  Antineoplastic activity of products derived from cellulose-containing materials: levoglucosenone and structurally-related derivatives as new alternatives for breast cancer treatment.

Authors:  Damian Ignacio Delbart; German Francisco Giri; Agostina Cammarata; Melisan Denise Pan; Lizeth Ariza Bareño; Natalia Loreley Amigo; Andrés Bechis; Alejandra Graciela Suarez; Rolando Ángel Spanevello; Marcela Solange Villaverde; Laura Beatriz Todaro; Alejandro Jorge Urtreger
Journal:  Invest New Drugs       Date:  2021-09-03       Impact factor: 3.850

4.  Tuning the activity of iminosugars: novel N-alkylated deoxynojirimycin derivatives as strong BuChE inhibitors.

Authors:  Ana I Ahuja-Casarín; Penélope Merino-Montiel; José Luis Vega-Baez; Sara Montiel-Smith; Miguel X Fernandes; Irene Lagunes; Inés Maya; José M Padrón; Óscar López; José G Fernández-Bolaños
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.